| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Cancer Research and Treatment Search > Browse Articles > Search



Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
Guiyun Sohn, Sei Hyun Ahn, Hee Jeong Kim, Byung-Ho Son, Jong Won Lee, Beom Seok Ko, Yura Lee, Sae Byul Lee, Seunghee Baek
Cancer Res Treat. 2016;48(4):1351-1362.   Published online April 6, 2016    DOI: https://doi.org/10.4143/crt.2015.444
                                 Cited By 4
A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
Changhoon Yoo, Sung-Bae Kim, Jin-Hee Ahn, Jeong Eun Kim, Kyung Hae Jung, Gyung-Yub Gong, Byung-Ho Son, Sei-Hyun Ahn, Seung Do Ahn, Hak-Hee Kim, Hee Jung Shin, Woo Kun Kim
Cancer Res Treat. 2015;47(3):406-415.   Published online November 27, 2014    DOI: https://doi.org/10.4143/crt.2014.073
                                 Cited By 4
Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Impact factor
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2PI